Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Analysis of Circulating Tumor Markers in the Blood

Next Previous
X
Search
Trial Profile

Analysis of Circulating Tumor Markers in the Blood

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; Everolimus; Fulvestrant; Palbociclib
  • Indications Advanced breast cancer; Bone cancer; Colorectal cancer; HER2 positive breast cancer; Lung cancer; Non-small cell lung cancer; Sarcoma; Soft tissue sarcoma; Solid tumours; Triple negative breast cancer; Uveal melanoma
  • Focus Biomarker; Proof of concept; Therapeutic Use
  • Acronyms ALCINA

    • Most Recent Events

    • 30 Sep 2024 Status changed from active, no longer recruiting to completed.
    • 01 Apr 2024 Results assessing the efficacy of fulvestrant and everolimus in CDK4/6i pre-treated mBC patients and circulating tumor DNA (ctDNA) changes throughout therapy, published in the Oncogene
    • 16 Nov 2023 Results assessing prognostic value of three liquid biopsy analytes (CTCs, sEVs, and ctDNA), alone and in combination in patient samples (n=54) from this study published in the British Journal of Cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top